OncoZenge AB (OSTO:ONCOZ) Gross-Profit-to-Asset % : 93.64% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. OncoZenge AB's annualized Gross Profit for the quarter that ended in Mar. 2025 was kr10.85 Mil. OncoZenge AB's average Total Assets over the quarter that ended in Mar. 2025 was kr11.59 Mil. Therefore, OncoZenge AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 93.64%.

OncoZenge AB Gross-Profit-to-Asset % Historical Data

The historical data trend for OncoZenge AB's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Gross-Profit-to-Asset % Chart

OncoZenge AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

OncoZenge AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial													-	-	-	-	93.64

Competitive Comparison of OncoZenge AB's Gross-Profit-to-Asset %

For the Biotechnology subindustry, OncoZenge AB's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoZenge AB's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

OncoZenge AB Gross-Profit-to-Asset % Calculation

OncoZenge AB's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	0	/	( (20.34	+	11.434)	/ 2 )
	=	0	/	15.887
	=	0.00 %

OncoZenge AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	10.852	/	( (11.434	+	11.743)	/ 2 )
	=	10.852	/	11.5885
	=	93.64 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

OncoZenge AB Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoZenge AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (OSTO:ONCOZ) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

8LY:Germany

Address

Gustavslundsvagen 34, Bromma, SWE, 167 51

Website

https://www.oncozenge.com

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines